Newton Biocapital is a Brussels-based venture capital firm investing in early-stage life sciences companies developing preventive and therapeutic treatments for chronic diseases, with operations in both Europe and Japan. The firm manages multiple funds (NBC I, II, and III) and bridges European and Japanese biotech ecosystems.
71% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (43% of deals).
Portfolio
13
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
DM
Daisuke Morishita
Venture Partner
TA
Tomoko Asaoka
Partner
JC
Jean Combalbert
Independent Director
PD
Pierre Detrixhe
Venture Director
AP
Alain Parthoens
Chief Executive Officer
GH
Guy Heynen
Chief Medical and Regulatory Officer
SS
Sadashi Suzuki
Japan Representative
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
14 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Tensegrity Pharma | Seed | — | Jan 2024 |
 Aboleris-Pharma | Series A | — | Sep 2023 |
| AAboleris Holdco | Series A | — | Sep 2023 |
 Deuteroncology | Series A | — | Jan 2023 |
 EditForce, Inc. | Series B | — | May 2021 |
 NEUVASQ | Series A | — | Jan 2021 |
| EditForce, Inc. | Unknown | — | Mar 2019 |
| EEditForce Inc. | Series B | — | Mar 2019 |
 Synergia | Series A | — | Feb 2018 |
 Acticor Biotech | Series B | — | — |
 EPICS THERAPEUTICS | Series A | — | — |
 AdipoPharma | Growth | — | — |
 AdipoPharma SAS | Growth | — | — |
 Cellaïon | Unknown | — | — |
Top Co-Investors
Wallonie Entreprendre4 shared
UTEC3 shared
Global Brain Corporation2 shared
ITOCHU Technology Ventures, Inc.2 shared
Caixa Capital Risc2 shared
KDDI1 shared
Mirae Asset1 shared
Karista1 shared
Fund+1 shared
Good Growth Capital1 shared
SFPIM1 shared
Noshaq1 shared
Last updated: 8 September 2026